摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-甲基-[2-(4-硝基-苯基)-乙基]-胺 | 85176-37-0

中文名称
N-甲基-[2-(4-硝基-苯基)-乙基]-胺
中文别名
甲基-[2-(4-硝基-苯基)-乙基]-胺;N-甲基-4-硝基苯乙胺
英文名称
N-methyl-2-(4-nitrophenyl)ethan-1-amine
英文别名
N-methyl-N-[2-(4-nitro-phenyl)-ethyl]-amine;N-methyl-4-nitrophenethylamine;N-methyl-2-(4-nitrophenyl)ethanamine
N-甲基-[2-(4-硝基-苯基)-乙基]-胺化学式
CAS
85176-37-0
化学式
C9H12N2O2
mdl
——
分子量
180.206
InChiKey
PTPPVTUXJDJAGY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    125-129 °C(Press: 1 Torr)
  • 密度:
    1.130±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    13
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    57.8
  • 氢给体数:
    1
  • 氢受体数:
    3

SDS

SDS:9e37c2ad319dc1b99f308cf90173a68a
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    N-甲基-[2-(4-硝基-苯基)-乙基]-胺 氢气potassium carbonate 、 sodium iodide 作用下, 以 乙醇二氯甲烷乙腈 为溶剂, 25.0 ℃ 、303.98 kPa 条件下, 反应 88.0h, 生成 多非利特
    参考文献:
    名称:
    Selective class III antiarrhythmic agents. 1. Bis(arylalkyl)amines
    摘要:
    A series of bis(arylalkyl)amines is described and their effects on prolonging effective refractory period in isolated cardiac tissue listed. Most compounds prolonged the cardiac action potential without significantly altering the maximum rate of depolarization and may be defined as selective class III antiarrhythmic agents. It was found that a particularly advantageous structural feature was to have a methanesulfonamido moiety on both of the aryl rings. Thus, compound 16 [1-(4-methanesulfonamidophenoxy)2-[N-(4-methanesulfonamidophene thyl)-N- methylamine]ethane] was selected for further investigations. The compound is highly potent and selective class III agent which acts by blockade of cardiac potassium channels.
    DOI:
    10.1021/jm00166a011
  • 作为产物:
    描述:
    2,2,2-trifluoro-N-(4-nitrophenethyl)acetamidesodium hydroxide 、 sodium hydride 作用下, 以 四氢呋喃甲醇 为溶剂, 反应 2.5h, 生成 N-甲基-[2-(4-硝基-苯基)-乙基]-胺
    参考文献:
    名称:
    Studies on Ca2+ channel antagonists. A 2-diazo-3,3,3-trifluoropropionamide derivative related to verapamil as a potential photoaffinity probe
    摘要:
    2-(3,4-Dimethoxyphenyl)-2-isopropyl-5-[N-[4-(N-methyl-2-diazo- 3,3,3-trifluoropropionamido)phenethyl]methyl-amino]valeronitril e (3), a potential photoaffinity probe for Ca2+ channels related to verapamil (1), was prepared from N-methyl-4-nitrophenethylamine (7) and 2-(3,4-dimethoxyphenyl)-2-isopropyl-5-(methanesulfonoxy)valeron itrile (12). Compound 3 showed concentration-dependent negative inotropic effects in rat right myocardial ventricular strips, EC50 = (1.05 +/- 0.33) X 10(-7) M (mean +/- SD), being slightly less potent than gallopamil (2), EC50 = (2.18 +/- 0.66) X 10(-8) M. It displaced [3H]gallopamil in myocardial membranes, Ki = (3.76 +/- 1.55) X 10(-8) M, compared to 2, Ki = (1.55 +/- 0.16) X 10(-8) M. Photoactivation at 265 nm reduced the recoverable binding of [3H]gallopamil to 26% compared to no effect on 2. This agent may be a useful photoaffinity probe to aid in further characterization of Ca2+ channels.
    DOI:
    10.1021/jm00164a064
点击查看最新优质反应信息

文献信息

  • Efficient Amination of Activated and Non‐Activated C(sp <sup>3</sup> )−H Bonds with a Simple Iron–Phenanthroline Catalyst
    作者:Lucie Jarrige、Zijun Zhou、Marcel Hemming、Eric Meggers
    DOI:10.1002/anie.202013687
    日期:2021.3.15
    available catalyst consisting of iron dichloride in combination with 1,10‐phenanthroline catalyzes the ring‐closing C−H amination of N‐benzoyloxyurea to form imidazolidin‐2‐ones in high yields. The C−H amination reaction is very general and applicable to benzylic, allylic, propargylic, and completely non‐activated aliphatic C(sp3)−H bonds, and it also works for C(sp2)−H bonds. The surprisingly simple method
    由二与 1,10-咯啉组合组成的现成催化剂可催化N-苯甲酰氧基的闭环 C-H 胺化,以高产率形成咪唑烷-2-酮。C−H 胺化反应非常普遍,适用于苯甲基、烯丙基、炔丙基和完全非活化的脂肪族 C(sp 3 )−H 键,并且也适用于 C(sp 2 )−H 键。这种令人惊讶的简单方法可以在敞口烧瓶条件下进行。
  • Anti-arrhythmic agents
    申请人:Pfizer Inc.
    公开号:US04959366A1
    公开(公告)日:1990-09-25
    A series of [N-alkyl-N-(nitro-, alkylsulphonamido, or amino-phenalkyl)amino]-alkyl, alkoxy or alkylthio phenyl derivatives having utility as anti-arrhythmic agents.
    一系列具有抗心律失常药物作用的[N-烷基-N-(硝基、烷基磺酰胺基或基苯基)基]-烷基、烷氧基或烷基基苯基衍生物
  • [EN] SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE<br/>[FR] DÉRIVÉS AMINÉS À SUBSTITUTION ARYLE ET PROCÉDÉS D'UTILISATION
    申请人:AMGEN INC
    公开号:WO2006012374A1
    公开(公告)日:2006-02-02
    The present invention provides classes of compounds, including-their pharmaceutically acceptable derivatives, useful for treating angiogenesis and related diseases such as cancer. Formula I and II wherein R is a 9- or 10-membered heterocyclyl ring selected from 7-isoquinolinyl,..2-methyl-3-oxo-2,3-dihydroindazol-6-yl, [1,6]-naphthydrin-3-yl, [1,7]-naphthydrin-2-yl, 1-oxo-2,3-dihydrobenzofuran-4-yl, 3-oxo-2,3-dihydrobenzofuran-5-yl, dihydro-benzodioxinyl, 6-quinazolinyl, 2-amino-6-quinazolinyl, 4-methylamino-6-quinazolinyl, 2,4-diamino-6 quinazolinyl, 3-oxo-3,4-dihydro-1,4-benzoxazin-6-yl, 2,2-difluoro-l;3-benzodioxol-5-yl and 2,2,3,3 tetrafluoro-2,3-dihydro-l,4-benzodioxin-6-yl, each of which is optionally substituted with one or more substituents selected from halo, haloakyl, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, N-dimethylamino-C1-6-alkyl, N-dimethylamino-C1-6-alkoxy, amino, alkyl-carbonylamino, morpholino-sulfonyl, amino-sulfonyl, oxazolyl, pyrrolyl,4 morpholinyl, carboxyl, cyano, and acetyl; wherein R1 in formula I is selected from unsubstituted or substituted phenyl, 5-6 membered heteroaryl, 9-10 membered bicyclic heterocyclyl and 11-14 membered tricyclic heterocyclyl, and R1 in formula II is selected from specific bicyclic heterocycles.
    本发明提供了一类化合物,包括其药用可接受的衍生物,用于治疗血管生成和相关疾病,如癌症。其中R为从7-异喹啉基、2-甲基-3-氧代-2,3-二氢吲哚-6-基、[1,6]-啶-3-基、[1,7]-啶-2-基、1-氧代-2,3-二氢苯并呋喃-4-基、3-氧代-2,3-二氢苯并呋喃-5-基、二氢苯并二氧杂环基、6-喹唑啉基、2-基-6-喹唑啉基、4-甲基-6-喹唑啉基、2,4-二基-6-喹唑啉基、3-氧代-3,4-二氢-1,4-苯并噁嗪-6-基、2,2-二-1,3-苯并二氧杂环-5-基和2,2,3,3-四-2,3-二氢-1,4-苯并二氧杂环-6-基中选择的9-或10-成员杂环基,其中每个基可选择地被一个或多个来自卤素、卤代烷基、C1-6烷基、C2-8烯基、C2-8炔基、N-二甲氨基-C1-6-烷基、N-二甲氨基-C1-6-烷氧基、基、烷基-羰基基、吗啉磺酰基、基磺酰基、噁唑基、吡咯基、吗啉基、羧基、基和乙酰基的取代基取代;其中式I中的R1从未取代或取代的苯基、5-6成员杂芳基、9-10成员双环杂环基和11-14成员三环杂环基中选择,式II中的R1从特定的双环杂环基中选择。
  • [EN] METHODS OF USING SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS<br/>[FR] PROCÉDÉS D'UTILISATION DE GLYCOPEPTIDES SEMI-SYNTHÉTIQUES EN TANT QU'AGENTS ANTIBACTÉRIENS
    申请人:BIOMARIN PHARM INC
    公开号:WO2011140009A1
    公开(公告)日:2011-11-10
    Methods of using semi-synthetic glycopeptides of formula I-XIV having antibacterial activity are described.
    描述了利用具有抗菌活性的半合成糖肽(化学式I-XIV)的方法。
  • Cdc25 photophatase inhibitors
    申请人:——
    公开号:US20040034103A1
    公开(公告)日:2004-02-19
    The invention concerns novel cdc25 phosphatase inhibitors, and in particular cdc25-C, which correspond to the general formula (I) wherein: A represents a carbocyclic aryl radical optionally substituted 1 to 3 times by one or more radicals independently selected among a halogen atom and an alkyl, hydroxy, alkoxy, alkylthio or NR 1 R 2 radical wherein R 1 and R 2 represent a hydrogen atom or an alkyl radical or R 1 and R 2 form together with the nitrogen atom a heterocycle of 4 to 7 members comprising 1 to 2 heteroatoms, the members required to complete the heterocycle being selected independently among the CR 3 R 4 —, —O—, —S and NR 5 -radicals, R 3 and R 4 representing independently each time they are involved a hydrogen atom or an alkyl, hydroxy, alkoxy, amino, alkylamino or dialkylamino radical, and R 5 representing independently each time it is involved a hydrogen atom or an alkyl radical, or A represents a phenyl radical substituted by a phenyl radical optionally substituted 1 to 3 times by one or more radicals selected independently among a halogen atom and an alkyl, hydroxy, alkoxy, alkylthio or NR 1 R 2 radical wherein R 1 and R 2 represent a hydrogen atom or an alkyl radical; B represents a —(CH 2 ) i —(CO)— or —NH—CO—(CH 2 ) n or —(CH 2 ) p and i and n being integers from 0 to 2 and p being an integer from 0 to 1; W represents a hydrogen atom or an alkyl radical; X represents a —(CH 2 ) q — or (CH 2 ) j —CO—(CH 2 ) r —, q being an integer from 1 to 4 and j and r being integers from 0 to 6; Y represents in particular a nitrophenyl, aminophenyl, alkylaminophenyl or dialkylaminophenyl radical or the radical (T). 1
    该发明涉及新型cdc25磷酸抑制剂,特别是cdc25-C,其对应于一般式(I),其中:A代表一个通过卤原子、烷基、羟基、烷氧基、烷基基或NR1R2基团中独立选择的一个或多个基团1至3次取代的碳环芳基,其中R1和R2分别表示氢原子或烷基基团,或者R1和R2与氮原子一起形成包括1至2个杂原子的4至7个成员的杂环,用于完成杂环的成员独立选择于CR3R4—、—O—、—S和NR5基团中,其中R3和R4在涉及时分别表示氢原子或烷基、羟基、烷氧基、基、烷基基或二烷基基基团,R5在涉及时表示氢原子或烷基基团,或者A代表一个苯基基团,该苯基基团通过一个或多个基团1至3次独立选择的卤原子和烷基、羟基、烷氧基、烷基基或NR1R2基团取代;B代表一个—(CH2)i—(CO)—或—NH—CO—( )n或—( )p的基团,其中i和n为0至2的整数,p为0至1的整数;W代表氢原子或烷基基团;X代表一个—( )q—或( )j—CO—( )r—的基团,其中q为1至4的整数,j和r为0至6的整数;Y特别代表一个硝基苯基、基苯基、烷基基苯基或二烷基基苯基基团或基团(T)。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫